The clinical–radiomics fusion model, which combines the clinical and DP radiomics model, has the best predictive performance for predicting the mutation status of KRAS in CRC, and the constructed model has been effectively verified by an internal validation cohort. The gene discussed is KRAS; the disease is colorectal carcinoma.